Endocrinology

Empagliflozin shows promise in improving insulin sensitivity in high-risk cardiovascular patients with dysglycaemia

Empagliflozin has potential as a safe first-line treatment for glucose regulation in patients with recently diagnosed dysglycaemia and a recent coronary event, according toa study. Empagliflozin has been recognized for its ability to reduce the risk of cardiovascular disease in patients with type 2 diabetes and high cardiovascular risk, though...